Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 154

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 154
---
88 million consists
of $0.92 million from PBAX and $0.96 million from Predecessor. The number of shares of Common Stock issued and amounts recorded on the
line within stockholders’ deficit are reflected below to arrive at the opening consolidated balance sheet of the Company.

    Convertible  

    Preferred Stock  
    Series A  
    Additional  
    Stock  

    Series
    A  
    Common
    Stock  
    Paid-in  
    Subscription  
    Accumulated  

    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Total 
  
    PBAX
    Closing Equity as of February 13, 2024 
     -  
    $-  
     2,741  
    $-  
    $547  
    $-  
    $(12,709,426) 
    $(12,708,879)
  
    Forfeiture
    of founders shares 
     -  
     -  
     (438) 
     -  
     -  
     -  
     -  
     - 
  
    Adjusted shares outstanding 
     -  
     -  
     2,303  
     -  
     547  
     -  
     (12,709,426) 
     (12,708,879)
  
    Shares
    issued as consideration in the Merger 
     -  
     -  
     4,038  
     1  
     47,238,749  
     -  
     -  
     47,238,750 
  
    Loss
    on VIE consolidation 
     -  
     -  
     -  
     -  
     -  
     -  
     (4,836,216) 
     (4,836,216)
  
    Expense
    IPR&D 
     -  
     -  
     -  
     -  
     -  
     -  
     (45,640,000) 
     (45,640,000)
  
    Reclassification of
    public shares 
     -